Employees: 40
Size Shattuck Labs (STTK) is a United States Health Care company (Biotechnology) with a market value of $455M, the 2747th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.47 on 18 Nov 2026.
Performance Over six months the shares fell 27.6%, against -1.8% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 19 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +4.9%).
Short interest Short interest is 10.6% of the free float (30 Oct 2026).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $1.00M | $5.72M | $1.66M | $652,000 |
| Revenue growth | — | -83% | +245% | +154% | — |
| Gross profit | -$3.46M | -$2.69M | $1.89M | -$2.38M | -$2.72M |
| EBITDA | -$68.6M | -$47.8M | -$76.5M | -$87.9M | -$100.0M |
| Net income | -$67.7M | -$48.8M | -$75.4M | -$87.3M | -$102M |
| Free cash flow | -$49.8M | -$40.0M | -$60.6M | -$81.6M | -$106M |
| Capital expenditure | $191,000 | $71,000 | $59,000 | $407,000 | $11.6M |
| Total debt | $2.45M | $2.42M | $3.41M | $4.20M | $4.90M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STTK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.5% | -5.4% | 4th lowest of 21 |
| 6-month return | -27.6% | -1.8% | 3rd lowest of 19 |
| Distance from 52-week high | -46.3% | -37.5% | 7th lowest of 21 |
| Revenue growth (TTM) | -100.0% | +4.9% | 2nd lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 509.6× | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | 9.9× | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | 3.3× | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 2.2× | 7.7% | +7.3% |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 4.0× | 2.1% | +0.5% |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | 22.7× | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | 13.3× | n/a | n/a |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | 3.1× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 2.6× | -19.5% | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 12.3× | 5.3% | +70.5% |